Key cannabis trade bodies have launched a UK-wide survey giving consumers the chance to have their say on the future of the industry.
In a joint statement, the British Hemp Alliance, Cannabis Trade Association, Northern Ireland Hemp Association and Scottish Hemp Association announced the launch of the Great British Consumer Survey on Tuesday 30 March.
The four major bodies, who collectively represent more than 1,000 domestic hemp and CBD companies, are gathering data on demand for CBD in the UK – specifically whether consumers prefer whole-plant products to synthetic or isolate-based extracts.
It comes in the week that the new novel food regulation is due to come into force, with all CBD companies expected to have an application submitted to the Food Standards Agency (FSA) by 31 March.
Only products with a successful application and listed on a public register due to be published by the FSA in April will be allowed to legally remain on the market moving forward.
Some in the industry fear this will force consumers of full-spectrum products (which contain a range of cannabinoids, including trace amounts of THC) onto a black market.
“Novel foods licensing for CBD products will see synthetic cannabinoids entering the food supply for the first time in the UK with no labelling requirement to differentiate from natural plant produced,” the bodies said in a joint statement.
“We believe consumers deserve to be informed of what they are putting into their bodies.
“We understand that novel foods products will be licensed based on their safety evaluation, but just as a consumer has the right to choose organic produce over conventionally grown, the same should apply to natural plant based, versus synthetically produced cannabinoid containing products.”
The organisations claim many consumers are not aware that synthetic CBD is about to enter the food supply and assume all CBD is derived from the hemp plant.
A recent survey conducted by the Scottish Hemp Association reported that 90 percent of Scottish consumers supported the proposal for a synthetic labelling requirement on these products.
“Consumers have not been informed that synthetically produced cannabinoids are about to enter the food supply for the first time,” Kyle Esplin, chair of Scottish Hemp Association commented.
“Following on from the Scottish Hemp Association’s survey which found that more than 90 percent of consumers support the proposal that products containing synthetically produced CBD should state this clearly on the label, in collaboration with British Hemp Alliance, Cannabis Trades Association and Northern Ireland Hemp Association, we have now launched the ‘Great British CBD survey 2021.
“We welcome feedback from consumers regarding synthetic cannabinoids in food supplements and look forward to presenting the results to Food Standards Authority and Food Standards Scotland.”
The last nationwide CBD consumer survey was conducted in 2019 by the Association for the Cannabinoid Industry (ACI).
Last week the four trade bodies rejected proposals for a 0.03 percent THC limit on CBD products put forward to the Home Office by the ACI, Centre for Medical Cannabis and the Conservative Drug Policy Reform Group, claiming it would be a “disaster” for the industry.
The survey takes less than two minutes to complete and can be found here.
New course offers expert advice on medical cannabis from doctors and patients
The Sativa Learning course includes insight from doctors and patients
A new online course on prescribing medical cannabis will offer a detailed insight into the industry from both clinicians and patients. Cannabis Health speaks to course creator and CEO Ryan McCreanor.
It will cover a comprehensive list of topics around cannabis as a medicine such as clinical evidence for medical cannabis, the practicalities of prescribing and side effects and contraindications.
The course, which will run online only, will also offer a variety of clinical and patient stories on a select list of conditions such as chronic pain, fibromyalgia, epilepsy, paediatric epilepsy, anxiety and post-traumatic stress disorder (PTSD).
Sativa Learning has already launched a successful online CBD course covering everything from the science behind the cannabinoid to UK regulations.
Ryan got the idea following his return from Canada to his hometown of Northern Ireland where he struggled to find decent quality CBD products. He started his career as a toxicology scientist before working for the Canadian government as an educator and trainer post legalisation in 2018.
“This was a way to bring a level of legitimacy to the industry by developing an accredited expert-led cannabis course,” said Ryan.
“The idea for the platform is that we want to provide education for all avenues of the cannabis industry. The CBD industry was a good place to start as I had a good level of knowledge myself so I put together a lot of the educational content myself.”
He continued: “I wanted to bring in real experts so we partnered with Professor Barnes and Hannah Deacon. All future courses will be CPD-credited. A lot of medical professionals will have to gain a certain amount of CPD points per year so they can take our course and feel comfortable that it is managed to a high started of further learning.”
As well as Hannah Deacon and Prof Barnes, the course also includes expert panels from Dr Dani Gordon who will speak about cannabis and oncology. Other classes will include Dr Elie Okirie speaking about epilepsy and Dr Evan Lewis on paediatric epilepsy. When it comes to the syllabus, the MCCS has put together the content for the cannabis course.
Ryan explained that they selected the conditions they included carefully to give a broad overview of common conditions.
He said: “We picked out 10 of the most common conditions for which cannabis is prescribed. We have fibromyalgia, chronic pain, cancer pain and women’s health issues. The doctors explain how they prescribe for that condition and have a number of patients who speak on camera about their experience.”
When it comes to panel discussions, courses or expert lead videos, it can often feel as if patients are forgotten. Ryan highlighted that this is a key part of the course.
“Not only do we have the doctors educating on cannabis but we have a follow-up with a patient talking about their experience,” he said.
“They discuss what life was like for them before medical cannabis, what their prescription is like and how this changed things for them.
“The industry should be all about the patients so we want to make sure that their voices are heard.”
The course will be fully online, with an option to learn as you go and break and save your progress whenever you are ready. At the end of the course, there will be an exam that will give you a presentation upon a passing grade. The exam is part of the CPD accreditation.
Ryan added: “Some people have blasted through our CBD course in one day where they just sit down and get through it all which can take up to six hours depending on your existing level of knowledge. This course is going to be quite a bit longer but you can do it all in one day or you could do a few hours a night for six months.”
The platform will be available for anyone who wants to learn about cannabis although Ryan explained that it may be more suited towards industry professionals.
He concluded: “There are no barriers to entry. The course is going to be available for whoever wants to learn about cannabis medicine. The language we use is heavily targeted towards the medical professionals as it is aimed at that audience to teach medical professionals about the basics of prescribing.”
The importance of peer-to-peer learning in medical cannabis
Alex Fraser, patient access lead at Grow Pharma on the importance of peer-to-peer learning.
The importance of peer-to-peer learning for healthcare professionals really cannot be exaggerated, writes Alex Fraser, patient access lead at Grow Pharma.
Doctors and nurses look to their peers for experienced guidance on how best to treat and manage their patients.
This is particularly pertinent in medical cannabis. CBMPs (cannabis-based medicinal products) are a family of medicines with a multitude of variables to consider when prescribing or managing patients. This is the reason we at Grow have brought together a broad range of CBMPs to ensure prescribers and patients have every option or tool they may require to manage symptoms.
Our portfolio now totals over 40 different CBMPs. Different THC: CBD ratios, different modes of administration, different strengths; understanding the implications of these differences is important.
At Grow we are dedicated to supporting HCPs and patients with CBMPs, utilising the wealth of experience and knowledge within our medical team, the cannabis-prescribing doctor’s and clinics we work alongside and the world-renowned producers whose medicines we distribute.
We’ve recently launched our HCP Portal, through which doctors can find out about upcoming educational events, see details of the medicines we supply and can access private secure forums to discuss the use of CBMPs with other HCPs.
There are already several online courses for healthcare professionals educating on cannabis medicines. In our view, these should be seen as an addition to peer-to-peer learning, not a replacement for it. Grow is pioneering peer-to-peer education in UK medical cannabis and, despite being a relatively new addition to the services we provide to HCPs, these sessions are already showing positive results with more and more prescribers entering the space having attended our first round of educational webinars.
Nothing can replicate the high level of learning achieved when a group is able to work through new concepts and material with other individuals engaged in the same work. Rather than clicking through videos and text, so much can be gained from being able to teach and be taught by one another, expanding perspectives and fostering meaningful connections with other HCPs.
Grow educational seminars
This is the premise behind Grow Pharma’s recently launched series of educational webinars. Aimed at HCP’s and focusing on various areas of interest within the field of cannabis medicines, these sessions include presentations from international experts, supported by some of the most respected producers of CBMPs from around the world including Tilray, Aurora and Columbia Care. So far, these sessions have focused on pain, rheumatology and mental health, with more coming up later this month and next.
Alongside detailed educational presentations, these sessions provide the opportunity to ask questions and discuss case studies and best practices with peers.
Upcoming educational webinar on clinical management of psychiatric conditions with cannabinoid-based medicines with Blake Pearson MD
With guidance from medical bodies on CBMP’s being limited, even with the recent guidance published by the BMJ on the use of CBMP’s in chronic pain, there is still a long way to go to engage the many specialist doctors who might prescribe cannabis medicines as well as GP’s who can refer patients to the specialist “cannabis clinics”. Whilst these doctors are the focus of our educational webinars, they are of course open to any and all HCPs interested in attending.
At Grow our mission is to give CBMPs the role in everyday medical practice that they deserve and to ensure that patients benefit from them wherever possible. There is a lot of work to be done to achieve this mission, but with experienced clinicians, expert producers and the engagement and support of institutions like the RSM we feel that we are poised to really make a difference; to grow the understanding of these medicines and their potential and most importantly to improve patient’s lives.
Grow and Integro Medical Clinics invite you to join us at the RSM on 11th Oct for a day of education on CBMPs in the treatment of pain from experts in the field and experienced UK prescribers.
Growing Cannabis Education and Understanding
We urge anyone interested in learning more to join our HCP Portal to find out about our upcoming digital and RW events and speak to other HCPS or contact us directly to request a space on one of our educational webinars.
Justin Bieber launches cannabis line with charitable focus
The limited-edition products will help to raise money for two charities
The Canadian singer announced he is launching a new cannabis pre-roll collection, Peaches, inspired by a single from his latest album.
Justin Bieber will also donate a portion of the proceeds to the Last Prisoner Project and a Veteran support charity.
He is working with the Los Angeles based company, Palms on special, limited edition, pre-rolled cannabis joints. The collection will be available throughout California. The specific strains are thought to include Indica, Sativa, with citrus terpenes and each pack will come with a branded lighter.
Bieber opened up about his struggle with mental health in a YouTube documentary series, Seasons, that aired last year. He also revealed he suffers from lyme disease.
In a statement, he said he wanted to enter the industry to help remove the stigma associated with cannabis use and hoped it could help younger people with mental health difficulties.
He said: “I’m a fan of Palms and what they are doing by making cannabis approachable and helping to destigmatise it – especially for the many people who find it helpful for their mental health. I wanted to make sure that I was doing something with them that felt genuine, and Peaches felt like a good place to start.”
A portion of sales from the products will support Veterans Walk and Talk, a group of veterans that advocate for cannabis as medicine. It will also support the Last Prisoners Project, a nonprofit organisation that aims to free people convicted of marijuana possession.
Justin Bieber and charity donations
The Veterans Walk and Talk organisation was established in 2016 in Southern California, Oakland and Sacramento. They offer veterans a way to take control of their health using exercise, cannabis, psychedelics and community. They use walking and talking therapies.
Each month they hold community outreach events such as veteran one on one walking events.
View this post on Instagram
The Last Prisoner Project
The Last Prisoner Project was founded to help those incarcerated for cannabis offences. They use a team of cannabis industry leaders, criminal and social justice advocates alongside policy and education experts. They are committed to freeing every last prisoner of the war on drugs which they estimate as 40,000 individuals.
View this post on Instagram
Celebrities and cannabis
Bieber joins a long line of celebrities entering the cannabis industry such as Snoop Dogg, Bella Thorne and Mike Tyson. The industry is thought to reach USD 70.6 billion by 2028, according to a report by market research company, Grand View Research, Inc.
In contrast to their American counterparts, British celebrities such as David Beckham have invested in CBD companies in recent months.
Introducing our new B2B title
- Menopause and medical cannabis – how we’re tackling the stigma
- ADHD: “I wasn’t naughty, the world just looked different to me”
- British footballer sentenced to 25 years in Dubai jail over CBD
- CBD brand teams up with Welsh artist to highlight emotions of lockdown
- Breast milk of THC-positive mothers not harmful to short-term health of infants – study
- Combining CBD and CBG for the ultimate entourage effect
News11 months ago
Community extends support to cannabis icon Rick Simpson
News1 year ago
NHS lines up cannabis medicine manufacturing
Case Studies2 years ago
CBD oil and fibromyalgia – a case study
News1 year ago
Cancer survivor claims cannabis oil helped her beat brain tumour
Insight1 year ago
I’ve gone from a wheelchair to walking thanks to cannabis
News9 months ago
UK grants second licence to grow high-THC medical cannabis
Feature1 year ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
News11 months ago
Living with chronic fatigue – my CBD story